Latest Conference Articles

The study revealed for the first time that triglycerides can be utilized as an independent predictor of cardiovascular risk—a landmark moment.

Dr Meletios A. Dimopoulos, discusses the use of ibrutinib combined with rituximab for the treatment of patients with Waldenström macroglobulinemia.

The poster presentations included a meta-analysis of 17 studies analyzing the cost-effectiveness and performance of the CGM system and a real-world examination of the trends its use.

Tim Dunn, PhD, discussed the benefits that the Freestyle Libre continuous glucose monitoring system provides for both the patients and providers

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

Murray Stewart, MD, spoke about his research into the hormone leptin—a major player in appetite and metabolism, with much that's still misunderstood about it.

The addition of features such as Bluetooth and Wi-Fi connectivity, in addition to cloud-to-cloud integration, is essential to improving diabetes devices.

Across the 6-month duration of the trial, weight loss was maintained across all dose levels, with patients that had the lowest baseline leptin levels benefitting the most.

How telehealth-friendly devices could change standard of diabetes care — with the help of physicians, patients, and the overall health care system.

Patients spent 11.2% more time in their target glucose range, and hypoglycemia was reduced from 5.1% to 1.9% overall, and 5.7% to 0.7% overnight.

How some of the most recent trial analysis narrows the clinical scope of GLP-1 and SGLT-2 targeting therapies.

Grenye O'Malley, MD, spoke about study data on insulin pen priming for patients with type 1 diabetes, noting that 80% of patients reported priming frequently.

The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois, June 1-5, 2018, featured data from numerous studies and advancements being made in rare cancers. Here are 5 key takeaways from the meeting.

Cardiovascular disease is the leading cause of death in women. And yet, the crux of concern for disease risk is designated to male patients.

Is there a relationship between polycystic ovary syndrome and diabetes? And if so, what are the variations in female patients?

The OPTIFAST meal replacement program resulted in better outcomes than the standard of care and a higher proportion of patients no longer meeting criteria for type 2 diabetes.

During the first 12 weeks of study, the investigated therapy had also reduced patient hypoglycemia event rates by 23% and low blood sugar event rates by 26% versus comparative therapy.

Despite several of these 2 medicines have proved to reduce cardiovascular risks, that has not been the case for all options, leading to confusion.

The Medtronic MiniMed 670G system was expanded for pediatric T1D patients, then reported positive real-world symptom management during ADA 2018.

Though the rate of suicidal ideation in pediatric patients with T1D is not significant from general population, girls reported twice as frequent rates.

Empagliflozin has reported positive outcomes in renal conditions and heart failure in T2D patients. Now what?

The absolute risk reduction for patients with diabetes and recent ACS was 2.3% when on the PCSK9 inhibitor plus statin therapy.

Post-hoc analyses from the EMPA-REG OUTCOME study found consistent benefits for the therapy in comorbidities versus placebo.

The chief medical officer of the Joslin Diabetes Center spoke about how providers communicate with their patients can affect their adherence to medications.

Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.

As physicians treat more diverse patient populations, the importance of communicating properly with patients can have resounding effects on outcomes and adherence.

Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.

Both the intention-to-treat and on-treatment principles reported significant blood sugar reductions from the oral GLP-1 analogue.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

More people achieved weight reduction of ≥5% and ≥10% with semaglutide in all BMI subgroups.